<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908191</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-101</org_study_id>
    <nct_id>NCT02908191</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers and Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will
      be a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the
      dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers
      are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging
      assessment of ABI-H0731 in non-cirrhotic, CHB patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>Up to 57 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for ABI-H0731</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-H0731 and Entecavir or Tenofovir Disoproxil Fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <arm_group_label>ABI-H0731</arm_group_label>
    <arm_group_label>ABI-H0731 and Entecavir or Tenofovir Disoproxil Fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABI-H0731</intervention_name>
    <arm_group_label>Placebo for ABI-H0731</arm_group_label>
    <other_name>Sugar pill manufactured to mimic the ABI-H0731 tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <arm_group_label>ABI-H0731 and Entecavir or Tenofovir Disoproxil Fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <arm_group_label>ABI-H0731 and Entecavir or Tenofovir Disoproxil Fumarate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy volunteers:

          1. Male or female between 18 and 65 years old with a BMI of 18-32kg/m2

          2. Must be in good health and not have any health condition which could interfere with
             the absorption, distribution or elimination of study drug, or with the clinical and
             laboratory assessments in this study

        CHB patients:

          1. Male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2

          2. Must have chronic hepatitis B with no history of clinical decompensation

          3. Must not have been treated for hepatitis B before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Assembly Biosiences</last_name>
    <email>clinicaltrials@assemblybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>September 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
